These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 23408582

  • 1. High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates.
    Neumann-Fraune M, Beggel B, Pfister H, Kaiser R, Verheyen J.
    J Med Virol; 2013 May; 85(5):775-9. PubMed ID: 23408582
    [Abstract] [Full Text] [Related]

  • 2. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V.
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [Abstract] [Full Text] [Related]

  • 3. Acute hepatitis B infection associated with drug-resistant hepatitis B virus.
    Xu Z, Liu Y, Xu T, Chen L, Si L, Wang Y, Ren X, Zhong Y, Zhao J, Xu D.
    J Clin Virol; 2010 Aug; 48(4):270-4. PubMed ID: 20580309
    [Abstract] [Full Text] [Related]

  • 4. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
    Cha CK, Kwon HC, Cheong JY, Cho SW, Hong SP, Kim SO, Yoo WD.
    J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
    [Abstract] [Full Text] [Related]

  • 5. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
    Zhao L, Li X, Cheng Y, Chen R, Shao J, Zhou Y, Li Q, Liao H, Zhao Y, Liu L, Su H, Liu Y, Liu Y, Xu D.
    Antiviral Res; 2018 Jun; 154():26-34. PubMed ID: 29630974
    [Abstract] [Full Text] [Related]

  • 6. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
    Yang JX, Liu BM, Li XG, Yan CH, Xu J, Sun XW, Wang YH, Jiao XJ, Yan L, Dong JP, Hou CS, Abuduheilili X, Li T, Zhuang H.
    Antivir Ther; 2010 Jun; 15(8):1171-8. PubMed ID: 21149924
    [Abstract] [Full Text] [Related]

  • 7. Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant.
    Sloan RD, Ijaz S, Moore PL, Harrison TJ, Teo CG, Tedder RS.
    Antivir Ther; 2008 Jun; 13(3):439-47. PubMed ID: 18572757
    [Abstract] [Full Text] [Related]

  • 8. Clinical characteristics and chronicity of acute hepatitis B induced by lamivudine-resistant strains.
    Luo Q, Zhong Y, Yang Y, Xiong Q, Hu Z, Lu W, Huang P, Zhang N.
    J Med Virol; 2012 Oct; 84(10):1558-61. PubMed ID: 22930503
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B.
    Coppola N, Tonziello G, Colombatto P, Pisaturo M, Messina V, Moriconi F, Alessio L, Sagnelli C, Cavallone D, Brunetto M, Sagnelli E.
    J Infect; 2013 Oct; 67(4):322-8. PubMed ID: 23796869
    [Abstract] [Full Text] [Related]

  • 11. Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?
    Lee GH, Aung MO, Dan YY, Lee YM, Mak B, Low HC, Lim K, Thwin MA, Tan PS, Lim SG.
    J Med Virol; 2013 Jan; 85(1):26-33. PubMed ID: 23023992
    [Abstract] [Full Text] [Related]

  • 12. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.
    Kim SS, Cho SW, Kim SO, Hong SP, Cheong JY.
    J Med Virol; 2013 Jan; 85(1):55-64. PubMed ID: 23096938
    [Abstract] [Full Text] [Related]

  • 13. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
    Suzuki F, Kumada H, Nakamura H.
    J Med Virol; 2006 Aug; 78(8):1025-34. PubMed ID: 16789011
    [Abstract] [Full Text] [Related]

  • 14. Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B.
    Su F, Dai J, Yang S, Jiang X, Cui X, Ning H, Li J, Huang M.
    J Med Virol; 2015 Sep; 87(9):1527-31. PubMed ID: 26032700
    [Abstract] [Full Text] [Related]

  • 15. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, Takeda T, Seki S, Kawada N, Shiomi S, Nishiguchi S.
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [Abstract] [Full Text] [Related]

  • 16. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes.
    Svicher V, Gori C, Trignetti M, Visca M, Micheli V, Bernassola M, Salpini R, Gubertini G, Longo R, Niero F, Ceccherini-Silberstein F, De Sanctis GM, Spanò A, Cappiello G, Perno CF.
    J Hepatol; 2009 Mar; 50(3):461-70. PubMed ID: 19041149
    [Abstract] [Full Text] [Related]

  • 17. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains.
    Herbers U, Amini-Bavil-Olyaee S, Mueller A, Luedde T, Trautwein C, Tacke F.
    J Viral Hepat; 2013 Feb; 20(2):141-8. PubMed ID: 23301549
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.
    Pollicino T, Isgrò G, Di Stefano R, Ferraro D, Maimone S, Brancatelli S, Squadrito G, Di Marco V, Craxì A, Raimondo G.
    Antivir Ther; 2009 Feb; 14(5):649-54. PubMed ID: 19704167
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.